News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Advanced Electroporation System for Vaccine Development at BTX



4/11/2012 3:15:10 PM

April 11, 2012 --The New AgilePulse® In Vivo Electroporation System possesses unique, variable pulse amplitude technology for vaccine delivery or gene therapy applications.

Patented Pulse Agile™ waveforms consist of multiple, low to high voltage pulses with variable pulse lengths, which promotes greater cell membrane poration; resulting in maximum transfection efficiency with minimal damage to the cells or tissues. Gene expression in skin is 100-fold higher1 when delivery is enhanced by electroporation compared to injection alone.

Features:

- Patented Pulse Agile® technology

- Resistance measurement for proper needle placement and reproducibility

- Specially designed needle arrays for intra-muscular or intra-dermal applications

Benefits:

- Enhanced immune response1

- Increased Ag-specific T-cell response1

- Gene expression is 100-fold higher1

Visit the BTX website at www.btxonline.com for more information on products, protocols or to view video tutorials for a variety of applications.

To learn more about this exciting new technology or other BTX electroporation or electrofusion products, contact: These new products are available exclusively through BTX Harvard Apparatus and Harvard Apparatus Distributors, worldwide. For complete specifications on this exciting new DNA Vaccine Delivery System, go to www.btxonline.com or contact the Harvard Apparatus Technical Support Department at techsupport@btxonline.com

BTX

84 October Hill Road

Holliston, Massachusetts 01746 USA

Toll Free: 800-272-2775

Phone: 508-893-8999 ext 167

Fax: 508-429-5732

E-mail: techsupport@btxonline.com

Web: www.btxonline.com

1Roos, A-K, et al., 2009 PLoS One 4(9)


Read at BioSpace.com


comments powered by Disqus
BTX
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES